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Running title: BRCA1 and BRCA2 sequencing in Scottish ovarian cancer patients 
 
Abstract 
Objective 
To determine the rate of germline BRCA1 and BRCA2 mutations in Scottish ovarian cancer 
patients before and after a change in testing policy. 
 
Design 
Retrospective cohort study. 
 
Setting 
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Four cancer/genetics centres in Scotland. 
 
Population 
Ovarian cancer patients undergoing germline BRCA1 and BRCA2 (gBRCA1/2) gene 
sequencing before 2013 (‘old criteria’; selection based solely on family history), after 2013 
(‘new criteria’; sequencing offered to newly presenting non-mucinous ovarian cancer 
patients) and the ‘prevalent population’ (who presented before 2013, were not eligible for 
sequencing under the old criteria but were sequenced under the new criteria). 
 
Methods 
Clinicopathological and sequence data were collected before and for 18 months after this 
change in selection criteria. 
 
Main Outcome Measures 
Frequency of germline BRCA1, BRCA2, RAD51C and RAD51D mutations. 
 
Results 
Of 599 patients sequenced, 205, 236 and 158 were in the ‘old criteria’, ‘new criteria’ and 
‘prevalent’ populations respectively. The frequency of gBRCA1/2 mutations was 30.7%, 
13.1% and 12.7% respectively. The annual rate of gBRCA1/2 mutation detection was 4.2 
before and 20.7 after the policy change. 48% (15/31) ‘new criteria’ patients with gBRCA1/2 
mutations had a Manchester score <15 and would not have been offered sequencing based 
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on family history criteria. In addition, 20 gBRCA1/2 patients were identified in the prevalent 
population. The prevalence of gBRCA1/2 mutations in patients >70 years was 8.2%. 
 
Conclusions 
Sequencing all non-mucinous ovarian cancer patients produces much higher annual 
gBRCA1/2 mutation detection with the frequency of positive tests still exceeding the 10% 
threshold upon which many family history based models operate. 
 
Funding 
No funding was received specifically for the conduct of this study. 
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Tweetable abstract: 
BRCA sequencing all non-mucinous cancer patients increases mutation detection five fold 
 
 
 
 
 
Introduction  
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Ovarian cancer is the fifth most common female cancer in Europe with 65,600 new 
diagnoses and 42,700 deaths in 2012.1 In Scotland, this equated to 610 new diagnoses2 and 
383 deaths.3  There is currently no effective screening programme, symptoms are non-
specific and patients usually present with disease that has spread beyond the pelvis. 
Germline BRCA1 and BRCA2 mutations (collectively referred to as gBRCA1/2 hereafter) 
confer a high risk of epithelial ovarian and breast cancer.  The prevalence of gBRCA1/2 
mutation in studies of populations (of women with epithelial ovarian cancer) with different 
genetic backgrounds ranges from 3-29% (table 1).4-16  
 
Identification of gBRCA1/2 mutation status in epithelial ovarian cancer has prognostic and 
predictive benefits for the individual and her family. Mutation carriers with ovarian cancer, 
have longer progression-free and overall survival compared to non-carriers,17, 18 and greater 
sensitivity both to platinum19, 20 chemotherapy and poly (ADP-ribose) polymerase (PARP) 
inhibitors. 21-23 Furthermore, identification of a gBRCA1/2 mutation enables unaffected 
relatives to be offered testing for the family mutation, and thus risk-reducing surgery or 
screening for breast and ovarian cancer.   
 
In many countries, the offer of publically-funded gBRCA1/2 testing is limited on resource 
grounds to those with a family history that indicates a specified level of risk (for example 
10%).24  In Scotland, as elsewhere, risk thresholds for full gBRCA1/2 gene testing 
have fallen over time, as sequencing costs have reduced, from 25% to 10%. Recent studies 
in a variety of ethnic backgrounds have shown that restricting testing to cases with a family 
history of breast or ovarian cancer results in 8-54% of mutation carriers being undetected.19, 
25-28 On the basis that the estimated prevalence of gBRCA1/2 mutations in high grade serous 
ovarian cancer (HGSOC) may exceed 10% (table 2), routine BRCA1 and BRCA2, 
sequencing was introduced in Scotland for all patients with non-mucinous ovarian cancer in 
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2012/13.   The objective of this study was to determine the rates of BRCA1 and BRCA2 
mutation detection in Scottish epithelial ovarian cancer patients both before and after this 
change in selection criteria. We also highlight different testing pathways including one where 
initial counselling is performed by the treating oncology team rather than clinical geneticists. 
 
Methods  
Different pathways for delivering testing to all newly diagnosed epithelial ovarian cancer 
patients were established in the East and West of Scotland (populations 2.9 and 2.5 million 
respectively). In the East of Scotland (centres in Edinburgh, Dundee and Aberdeen), patients 
with non-mucinous epithelial ovarian cancer were offered routine testing from 01/11/2012 
(Edinburgh), 01/06/2013 (Dundee) and 01/12/2013 (Aberdeen).  In Edinburgh and Dundee, 
patients receive counselling from their medical oncologist, and, after receiving written patient 
information, give written consent. In Aberdeen, the process is broadly similar with 
oncologists introducing the test, arranging blood sampling but then referring the patient to 
clinical genetics for a telephone consultation to complete the consenting process. In the 
West of Scotland, universal testing started in March 2013.  All patients with non-mucinous 
ovarian cancer are referred to the genetics team, and mutation testing is only initiated 
following counselling by a genetic counsellor. 
 
DNA testing was performed in CPA accredited laboratories in Aberdeen and Glasgow. DNA 
was extracted from blood samples, PCR amplified and sequenced bi-directionally using 
standard Sanger sequencing technology.  Sequence data was analysed using Mutation 
Surveyor (Soft Genetics) and variants assessed for pathogenicity according to the Practice 
Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in 
Clinical Molecular Genetics (ACGS /VGKL 2013). MLPA (MRC Holland) was used to test for 
exonic and whole gene deletions.  The DNA of patients found not to have a deleterious 
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BRCA1 or BRCA2 mutation was then sequenced for RAD51C and RAD51D mutations. 
Patients found to have a deleterious mutation or reported variant of uncertain significance in 
any of the four genes were subsequently referred to clinical genetics for a face to face 
consultation (as well as any other patients who had a significant family history or who wished 
a further discussion). Testing for RAD51C and RAD51D mutations in the West of Scotland 
was restricted to those with two or more family members with history of ovarian cancer. 
 
Data resulting from the first 18 months of testing following the change in selection criteria 
were collected from each centre (with the exception of Aberdeen, which instituted the 
change in practice later and from which 9 months of data were collected) and compared to 
historical data from the preceding period when access to BRCA1/2 sequencing was 
dependent upon family history alone. 
 
For each locality, the number and frequency of positive tests was determined for three 
specific cohorts:  
1) ‘Old criteria’ patients: those patients sequenced before the change in process (when 
eligibility for testing was based on family history). The period of testing for these 
patients was from September 1997 until the date of change of selection criteria, as 
specified above. 
2) ‘Prevalent population’ patients: The prevalent population of patients who did not fit 
previous criteria for sequencing but had a diagnosis of HGSOC and were still being 
reviewed in clinic following the change in selection criteria.   
3) ‘New criteria’ patients: Patients tested under the new selection process during their 
first line treatment.   
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Results  
A total of 631 patients were offered or referred for genetic testing.  Of these, there were 10 
active refusers (declined testing at the time it was offered, either by the medical oncologist in 
the East [n = 3] or the clinical geneticist in the West [n = 7]), 21 passive refusers (patients in 
the West who were referred to clinical genetics but did not reply to correspondence) and 1 
patient who was offered testing but died before it could be performed. 599 remaining ovarian 
cancer patients were included in the analysis (table 3). This comprised 205 ‘old criteria’ 
patients and 394 tested following the change in selection criteria (236 ‘new criteria’ patients 
and 158 ‘prevalent population’ patients). In terms of the different pathways for delivering the 
genetic sequencing, of the 394 patients sequenced following the change in criteria, 251 were 
sequenced in the East and 143 in the West of Scotland. 
 
Across Scotland, the frequency of gBRCA1/2 mutation detection in the old criteria patients 
was 30.7% in the ‘old criteria’ patients, 12.7% in the ‘prevalent’ population and 13.1% in the 
‘new criteria’ population. In the East of Scotland, the gBRCA1/2 mutation detection rate was 
9.4% in the prevalent population and 11.0% in the new criteria patient group.  In the West of 
Scotland, by comparison, the gBRCA1/2 mutation rate was 17.7% in the prevalent 
population and 17.3% in the new criteria group. It is worth noting that the frequency of 
deleterious gBRCA2 mutations in the West of Scotland patients following the change in 
selection criteria was strikingly high at 11.2% in the prevalent population and 13.5% in the 
new criteria patients, compared to 3.1% and 3.9% respectively in the East of Scotland. 
Overall, the annual rate of gBRCA1/2 mutation detection was 4.2 and 20.7 patients per year 
before and after the change in selection criteria respectively. Only two mutations in 
RAD51C/D were identified following the change in testing criteria, one each in the prevalent 
and new criteria populations (approximate 1% test positivity rate).  Variants of Unknown 
Significance were seen in 5.4% (11 of 205, 4 BRCA1, 7 BRCA2) patients tested in the old 
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criteria, 9.4% in the prevalent population (15 of 158, 3 BRCA1, 12 BRCA2) and 6.4% in the 
new criteria patients (15 of 236, 4 BRCA1, 11 BRCA2).   
 
Manchester Score30 was recorded for all patients identified to have a pathogenic mutation. 
48% (15/31) new criteria patients with gBRCA1/2 mutations had a Manchester score 
<15(table 4). Thus, if our new patients had been tested on Manchester score alone, almost 
half the mutation carriers would have been missed.  In addition, 20 patients with gBRCA1/2 
mutations in the prevalent population were identified retrospectively over this 18 month 
period. None of these had previously been identified as eligible for testing, although 
interestingly 11 of these patients had a Manchester score ≥15 when formally assessed by 
clinical genetics. Only after sequencing became standard of care were these patients 
referred.  Thus, 39 patients with gBRCA1/2 mutations were identified across Scotland over 
this 18 month period who would not have been tested if the new policy had not been 
implemented.  
When the histology of the mutation carriers was considered across all three cohorts 
(Appendix S1), all the mutation carriers were found to have high grade serous ovarian 
cancer (102 out of 518, 19.7%) or epithelial ovarian cancer not otherwise specified (largely 
from the historical ‘old criteria’ cohort; 12 out of 44, 27.3%). No deleterious BRCA1/2 
mutations were detected in seven patients with carcinosarcoma, nine with clear cell ovarian 
cancer or 14 with low grade serous ovarian cancer. In addition five patients with mucinous 
tumours, one with a Brenner tumour and one with a STIC had been sequenced (some in the 
‘old criteria’ cohort). None of these patients harboured deleterious mutations. 
The age at diagnosis of all tested patients was recorded.  Across all cohorts, 13/114 (11.4%) 
patients with pathogenic BRCA1 or BRCA2 mutations were aged over 70, and the rate of 
identified pathogenic mutations in this age group was 8.2% (13 pathogenic mutations from 
159 patients tested).  When the frequency of BRCA1/2 mutation carriers without a family 
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history of breast or ovarian cancer was considered by age group across all three cohorts 
only the 30-39, 40-49, 50-59 and 60-69 age groups had a percentage of mutation carriers in 
excess of 10% (<30 years 0/6 [0%]; 30-39 years 5/10 [50%]; 40-49 years 5/42 [11.9%]; 50-
59 years 20/85 [23.5%]; 60-69 years 12/101 [11.9%]; 70-79 years 3/80 [3.8%]; >80 years 
0/13 [0%]). 
 
Discussion  
Main findings 
Across Scotland, the frequency of gBRCA1/2 mutation detection was 13.1% in patients 
presenting with non-mucinous ovarian cancer. The annual rate of gBRCA1/2 mutation 
detection was 20.7 compared to 4.2 when selection for sequencing was based solely upon 
family history criteria. The acceptance of the offer of sequencing was high with only 2% 
active refusal. In the West of Scotland where a step of active participation in the process was 
required there were an additional 12% of patients who passively refused sequencing. 
Analysis of Manchester scores showed that 48% of new mutation carriers would not have 
been offered sequencing if selection had been based on family history alone. The gBRCA1/2 
mutation rate in the prevalent population was 12.7% which was surprising since these 
patients had been overlooked for sequencing when selection was based upon family history 
criteria, although interestingly, 55% of these patients did have a significant family history 
(Manchester score >15) when formally assessed by the clinical genetics team . Finally, the 
incidence of gBRCA1/2 mutations in non-mucinous ovarian cancer patients aged over 70 
was 8.2%. 
 
Strengths and limitations 
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The strengths of this study are its size, the fact that it captured all patients offered 
sequencing across Scotland (limiting the potential for selection bias in tertiary referral 
centres) and that the data for the majority of patients were retrieved from prospectively 
collected clinical databases with case note searching only required in a minority of cases. 
The limitations of this study are its retrospective nature, the fact that patient satisfaction was 
not assessed and the fact that the criteria for selecting patients for sequencing differed 
slightly between centres (particularly comparing the East to the West) although this did allow 
the pros and cons of the different mainstreaming techniques to be highlighted. 
 
Interpretation 
At a time when BRCA1/2 mutation status determines access to effective new drugs in the 
form of PARP inhibitors (olaparib was licensed in 2014 and approved for reimbursement in 
the UK in 2016), it is imperative that as many ovarian cancer patients as possible are offered 
the chance of sequencing. In Scotland, all patients diagnosed with non-mucinous ovarian 
cancer are now routinely offered germline BRCA1/2 sequencing, an approach enshrined in 
new national guidelines. 31  Scotland is one of the first countries to offer this service as a 
national standard of care.  The gBRCA1/2 mutation rate in newly diagnosed Scottish ovarian 
cancer patients of 13.1% justifies the switch away from family history based patient selection 
criteria for sequencing.  
Two broad models for routine testing have been implemented, with local variation driven by 
resource and clinician preference. In the West, all patients are referred to Clinical Genetics 
for counselling and consent before testing, whilst in East Scotland oncologists provide 
genetic counselling at the first clinic visit, obtain written consent and offer the test.  Patients 
who are subsequently found to harbour a germline mutation return to Clinical Genetics (in 
the West) or are referred de novo to Clinical Genetics in the East in order that they can 
receive personal counselling regarding their breast cancer risk and also in order to facilitate 
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counselling and cascade testing for relatives.   In both test models, we find that testing is 
acceptable to patients (although patient satisfaction was not assessed in this study) and 
take-up rates are high. It is noticeable that the take-up rate is lower in the West, where 
testing requires active patient participation (patients must reply to invitation from Genetics 
and attend an appointment or have a telephone consultation before testing can commence).  
. The concept of pre-test counselling being provided by non-geneticists in order to streamline 
the process so that the genetics team are able to focus on mutation carriers rather than a 
cohort of patients, many of whom will not carry a mutation is gathering general acceptance 
with other studies demonstrating high levels of patient satisfaction.32 
 
Previous studies have identified higher mutation rates in ovarian cancer patients than 
identified in East of Scotland, 19, 26, 33 but broadly similar to those in West Scotland.  
However, many of these previous studies recruited patients retrospectively and were based 
in tertiary referral centres that were not the sole ovarian cancer care providers in their 
geographical location. In addition, it was noted that a number of the identified patients could 
not be enrolled as they had died, thus providing a selection bias towards gBRCA1/2 
mutation carriers who have superior survival to non-carriers. 17  Many of these studies have 
also been limited by poor uptake of testing giving the potential for further selection bias.  In 
East Scotland, the sequencing uptake rate was 98.8% (3 patients declined testing) 
suggesting that gBRCA1/2 mutation rates in genuinely unselected patients may be slightly 
lower than previously suggested. Nevertheless the case detection rate still met the cost-
effectiveness threshold for family benefit, justifying the cost of testing on those grounds 
alone. 
 
The gBRCA1/2 mutation rate in the prevalent group (12.7%) was higher than expected.  We 
had hypothesised that patients with a strong family history would have been tested under the 
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previous schedule, thus reducing the remaining gBRCA1/2 positive pool in untested patients.  
An alternative explanation, suggested by the incidence of Manchester scores ≥15 in the 
patients who tested positive in the prevalent group, is that ascertainment of family history by 
the oncologists was incomplete. By making sequencing routine, the potential for missing 
patients due to inaccurate family history assessment is circumvented.  
Historically, RAD51C and RAD51D germ line sequencing has been performed in Scotland 
because of the increased ovarian cancer risk in carriers.34, 35 With a frequency of mutation of 
either gene of around 1%, it could be debated whether this is a cost-effective exercise. 
However, with evidence emerging regarding the PARP inhibitor sensitivity of ovarian 
tumours harbouring RAD51C mutations in particular36 the results have implications both for 
the patients and their families. 
 
The protocol for germ line BRCA1 and BRCA2 sequencing of ovarian cancer patients differs 
across the UK. Many regions of England, Wales and Northern Ireland continue to sequence 
only patients with a significant family history, a small number sequence all non-mucinous 
ovarian cancer patients32 and others impose age restrictions for germline testing.  Here, we 
show that the rate of germline mutation was 8.2% in those over 70 years, and that 11.4% of 
all mutation carriers were over 70 at the time of diagnosis.  The oldest mutation carrier 
identified was 84 years old.  Our data contrast with a recent study from the East of England, 
where only 1 of 86 women over the age of 70 carried a pathogenic mutation,37 which led the 
authors to conclude that testing should be restricted to those under 70 years in the absence 
of positive family history.  Our results are more in line with those of Norquist et al, who 
identified BRCA1/2 mutations in over 5% of their population aged 70 – 79.38  Thus, overall, 
we advocate a policy whereby testing is offered to patients regardless of their age at 
diagnosis. 
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Conclusion 
We demonstrate that routine nationwide testing of ovarian cancer patients for gBRCA1/2 
mutations offers prognostic and predictive information and meets cost-effectiveness 
thresholds already widely in place in UK genetic healthcare. The strategy detects mutation in 
13 per 100 cases, 48% of whom would not be identified through case selection on the basis 
of family history alone.  Testing in the oncology setting, without requirement for formal pre-
test genetic counselling, or a mixed consent model, is feasible and reduces both the 
potential for referral bias and the burden upon Clinical Genetics departments.  We propose 
that all women with non-mucinous ovarian cancer should be offered germline BRCA 
mutation testing as part of routine clinical care prior to the commencement of chemotherapy. 
 
Acknowledgements 
We thank Tzvyia Rye for data entry and retrieval from the Edinburgh Ovarian Cancer 
Database and Cancer Research UK for funding of this database.  We also thank Sarah 
Gibson for collecting the West of Scotland data. 
 
Disclosure of interests 
MM has sat on advisory boards for Roche and delivered lectures for Boehringer Ingelheim. 
CG has sat on advisory boards for Roche, AstraZeneca, Nucana, Tesaro, Foundation One 
and Clovis and has delivered lectures for Roche, Tesaro and AstraZeneca. CG has also 
received research funding from AstraZeneca, Novartis, Tesaro, Nucana and Aprea. CB has 
sat on advisory boards for AstraZeneca. The other co-authors have no conflicts of interest to 
disclose. The ICMJE disclosure forms are available to view online as supporting information. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Contribution to authorship 
Study design: KR, CG  
Data acquisition: KR, PS, CYT, CB, DS, TFP, RD, MM, FN, RG, NR, AS, MP, TMcG, MF, 
ZM, IMcN, CG 
Data analysis: KR, PS, CB, DS, IMcN, CG  
Manuscript preparation: KR, PS, ZM, IMcN, CG   
All authors reviewed the manuscript before submission. 
 
Details of ethics approval 
We have been informed by South East Scotland Research Ethics Service that studies in 
BRCA-defective ovarian cancer patients using data obtained as part of usual care do not 
require NHS ethical review. As such, no independent ethical approval for this study was 
sought. 
 
Funding 
No funding was received specifically for the conduct of this study. 
 
References 
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. 
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European 
journal of cancer. 2013 Apr;49(6):1374-403. 
2. Information Services Division NNSS. Cancer Incidence 2012.  2014  [cited; Available from: 
https://isdscotland.scot.nhs.uk/Health-Topics/Cancer/Publications/2014-04-29/2014-04-29-Cancer-
Incidence-Report.pdf?44990175963 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
3. Information Services Division NNSS. Cancer Mortality in Scotland 2013  [cited; Available 
from: https://isdscotland.scot.nhs.uk/Health-Topics/Cancer/Publications/2013-11-26/2013-11-26-
CancerMortality-Report.pdf?44990175963] 
4. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a 
population-based case series of breast and ovarian cancer. European journal of cancer. 2000 
Jun;36(10):1200-8. 
5. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, et al. Effect of BRCA 
mutations on the length of survival in epithelial ovarian tumors. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 2002 Jan 15;20(2):463-6. 
6. Bjorge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, et al. BRCA1 mutations in ovarian 
cancer and borderline tumours in Norway: a nested case-control study. British journal of cancer. 
2004 Nov 15;91(10):1829-34. 
7. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 
mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of 
ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2008 Jan 1;26(1):20-5. 
8. Jacobi CE, van Ierland Y, van Asperen CJ, Hallensleben E, Devilee P, Jan Fleuren G, et al. 
Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort. 
Genetics in medicine : official journal of the American College of Medical Genetics. 2007 
Mar;9(3):173-9. 
9. Khoo US, Ngan HY, Cheung AN, Chan KY, Lu J, Chan VW, et al. Mutational analysis of BRCA1 
and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Human mutation. 
2000 Jul;16(1):88-9. 
10. Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, Emerich J, et al. Prognostic impact 
of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian 
carcinoma. Cancer. 2005 Sep 1;104(5):1004-12. 
11. Menkiszak J, Gronwald J, Gorski B, Jakubowska A, Huzarski T, Byrski T, et al. Hereditary 
ovarian cancer in Poland. International journal of cancer Journal international du cancer. 2003 Oct 
10;106(6):942-5. 
12. Metcalfe KA, Fan I, McLaughlin J, Risch HA, Rosen B, Murphy J, et al. Uptake of clinical 
genetic testing for ovarian cancer in Ontario: a population-based study. Gynecologic oncology. 2009 
Jan;112(1):68-72. 
13. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral 
contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 
mutation. The New England journal of medicine. 2001 Jul 26;345(4):235-40. 
14. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, et al. BRCA1, 
BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
cancer population: relationship to family history and implications for genetic testing. American 
journal of obstetrics and gynecology. 1998 Apr;178(4):670-7. 
15. Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, et al. Contribution of BRCA1 
mutations to ovarian cancer. The New England journal of medicine. 1997 Apr 17;336(16):1125-30. 
16. Van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, et al. Prevalence of founder 
BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. International 
journal of cancer Journal international du cancer. 2000 Jun 1;86(5):737-40. 
17. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association 
between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. 
Jama. 2012 Jan 25;307(4):382-90. 
18. Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, et al. 
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial 
ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2015 Feb 1;21(3):652-7. 
19. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation 
frequency and patterns of treatment response in BRCA mutation-positive women with ovarian 
cancer: a report from the Australian Ovarian Cancer Study Group. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology. 2012 Jul 20;30(21):2654-63. 
20. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al. "BRCAness" 
syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of 
patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Dec 
1;26(34):5530-6. 
21. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral 
poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and 
recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):245-51. 
22. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose 
polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with 
platinum-free interval. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2010 May 20;28(15):2512-9. 
23. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib 
maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a 
preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The 
Lancet Oncology. 2014 Jul;15(8):852-61. 
24. Familial Breast Cancer. Classification and care of people at risk of familial breast cancer and 
management of breast cancer and related risks in people with a family history of breast cancer. 
National Institute for Clinical Excellence; 2013. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
25. Malander S, Ridderheim M, Masback A, Loman N, Kristoffersson U, Olsson H, et al. One in 10 
ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in 
Southern Sweden. European journal of cancer. 2004 Feb;40(3):422-8. 
26. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and 
BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. Journal 
of the National Cancer Institute. 2006 Dec 6;98(23):1694-706. 
27. Soegaard M, Kjaer SK, Cox M, Wozniak E, Hogdall E, Hogdall C, et al. BRCA1 and BRCA2 
mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases 
from Denmark. Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2008 Jun 15;14(12):3761-7. 
28. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes 
for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel 
sequencing. Proceedings of the National Academy of Sciences of the United States of America. 2011 
Nov 1;108(44):18032-7. 
29. Holland ML, Huston A, Noyes K. Cost-effectiveness of testing for breast cancer susceptibility 
genes. Value in health : the journal of the International Society for Pharmacoeconomics and 
Outcomes Research. 2009 Mar-Apr;12(2):207-16. 
30. Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, et al. A new scoring system for 
the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. 
Journal of medical genetics. 2004 Jun;41(6):474-80. 
31. (SIGN) SIGN. SIGN 135 Management of epithelial ovarian cancer. Healthcare Improvement 
Scotland 2013. 
32. George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, 
robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Scientific 
reports. 2016 Jul 13;6:29506. 
33. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 
mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005 Dec 
15;104(12):2807-16. 
34. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations 
in RAD51D confer susceptibility to ovarian cancer. Nature genetics. 2011 Aug 7;43(9):879-82. 
35. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline 
mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility 
gene. Nature genetics. 2010 May;42(5):410-4. 
36. Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, et al. Secondary 
Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP 
Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer discovery. 2017 Sep;7(9):984-98. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
37. Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, et al. New 
paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in 
Epithelial Ovarian Cancer (GTEOC) study. Journal of medical genetics. 2016 Oct;53(10):655-61. 
38. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited Mutations 
in Women With Ovarian Carcinoma. JAMA oncology. 2016 Apr;2(4):482-90. 
39. Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, et al. BRCA1 and 
BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. European journal of 
human genetics : EJHG. 2001 Jun;9(6):424-30. 
40. Rafnar T, Benediktsdottir KR, Eldon BJ, Gestsson T, Saemundsson H, Olafsson K, et al. BRCA2, 
but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. 
European journal of cancer. 2004 Dec;40(18):2788-93. 
  
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1. Incidence of germline BRCA1 or BRCA2 mutations in previous retrospective 
ovarian cancer studies 
 
Study Population Year Patients BRCA1 BRCA2 BRCA1&2 Sequencing method 
Alsop 19 Australia 2012 1001 88 (8.8%) 53 (5.3%) 141 (14%) HRM/MLPA 
Malander 25 Sweden 2004 161 9 (5.6%) 4 (2.4%) 13 (8%) TS/DHPLC/PTT 
Risch 26 Canada 2006 977 75 (7.7%) 54 (5.5%) 129 (13%) TS/DGGE/PTT 
Stratton 15 London, UK 1997 374 12 (3%) - 12 (3%) HA 
Anton-Culver 4 USA 2000 120 4 (3.3%) - 4 (3.3%) TS 
Bjorge6 Norway 2004 478 19 (4%) - 19 (4%) CSCE 
Jacobi 8 Netherlands 2007 85 3 (3.5%) 2 (2.4%) 5 (5.9%) CSCE 
Majdak10 Poland 2005 205 18 (8.8%) 0 18 (8.8%) CSGE 
Chetrit7 
Israel (Non-
Askenazi) 
2008 174 13 (7.5%) 3 (1.7%) 16 (9.2%) 
TS* 
Rubin 14 Philidelphia 1998 116 10 (8.6%) 1 (0.9%) 11 (9.5%) SSCP 
Metcalfe 12 Canada 2009 416 29 (7%) 
 
11 (2.6%) 
 
41 (9.9%) 
TS/DGGE/DHPLC/FM
PA 
Van der Looij16 Hungary 2000 90 10 (11%) 0 10 (11%) HA/SSCP 
Khoo9 China 2000 53 6 (11.3%) 1 (2%) 7 (13%) PTT and sequencing 
Menkiszak11 Poland 2003 364 49 (13.5%) - 49 (13.5%) 
 
TS* 
Ben David 5 Israel 2002 896 19.4% 6.7% 234 (26.1%) TS* 
Modan13 Israel  2001 840 
182 
(21.7%) 
64 (7.6) 244 (29%) 
TS* 
 
HA: heteroduplex analysis; TS: targeted sequencing; CSCE: capillary electrophoresis 
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CSGE: conformational sensitive gel electrophoresis; SSCP: single-strand conformational 
polymorphism analysis; DGGE: gradient gel electrophoresis; DHPLC: denaturing high-
performance liquid chromatography; FMPA: Fluorescent multiplexed-PCR analysis; PTT: 
protein truncation test 
HRM: high resolution melting; MLPA: multiplex ligation-dependent probe amplification 
 
* Founder mutations only 
 
Table 2. Incidence of germline BRCA1 or BRCA2 mutations in previous retrospective 
serous ovarian cancer studies 
 
Study Population Year Patients BRCA1 BRCA2 BRCA1&2 
Sequencing 
method 
Malander 25 Sweden 2004 105 (serous) 7 (6.7%) 1 (0.9%) 8 (7.6%) TS/DHPLC/PTT 
Sarantau 39 Finland 2001 118 (serous) 8 (6.8%) 2 (1.7%) 10 (9%) TS*/PTT 
Rafnar 40 Iceland 2004 97 (serous) 2 (2%) 8 (8.2%) 10 (10.3%) TS* 
Pal 33 Florida, USA 2005 121 (serous) 14 (11.6%) 6 (4.96) 20 (16.5%) TS 
Alsop 19 
Australia 
2012 709 (serous) 
(433 HGS) 
74 (10%) 
 
44 (6.2%) 
 
18/709 (16.6%) 
98/433 (22.6%) 
HRM/MLPA 
Risch26 Canada 2006 610 (serous) 62 (10%) 48 (7.9%) 110 (18%) TS/DGGE/PTT 
 
TS: targeted sequencing; DHPLC: denaturing high-performance liquid chromatography;  
PTT: protein truncation test; HRM: high resolution melting; MLPA: multiplex ligation-
dependent probe amplification 
* Founder mutations only 
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Table 3. Frequency of genetic mutations in Scottish ovarian cancer patients. 
 
 East of Scotland West of Scotland Combined analysis 
 Old criteria 
Prevalent 
population 
New 
criteria 
Old criteria 
Prevalent 
population 
New criteria Old criteria 
Prevalent 
population 
New 
criteria 
Number of patients 
tested 
138 96 155 67 62 81 205 158 236 
BRCA1 mutation# 
33 
(23.9%) 
6  
(6.2%) 
12* 
(7.7%) 
8 
(11.9%) 
4  
(6.5%) 
3 (3.7%) 
41 
(20.0%) 
 10 (6.3%) 
15* 
(6.4%) 
BRCA1 VUS 4 (2.9%) 
3*  
(3.1%)   
3 (1.9%) 0 0 1 (1.2%) 4 (2.0%) 
3  
(1.9%) 
4 (1.7%) 
BRCA2 mutation# 
15 
(10.9%) 
3  
(3.1%) 
6* 
(3.9%) 
7 
(10.4%) 
 7 (11.2%) 
11 
(13.6%) 
22 
(10.7%) 
 10 (6.3%) 
17* 
(7.2%) 
BRCA2 VUS 5 (3.6%) 10** (10.4%) 8 (5.2%) 
2  
(3.0%) 
2  
(3.2%) 
3 (3.7%) 7 (3.4%)  12 (7.6%) 
11 
(4.7%) 
RAD51C/D 
mutation#¥ 
1  
(NK) 
0 1 (0.7%) 0 
1  
(16.7%) 
0 1     (NK) 
1  
(1.1%) 
1   
(0.7%) 
RAD51 C/D VUS 
2  
(NK) 
6  
(6.9%) 
4 (2.9%) 0 0 0 2     (NK) 
6  
(6.5%) 
4   
(2.8%) 
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# Mutations known to be pathogenic.  
*1 patient had pathogenic mutations in both BRCA1 and BRCA2 
**1 patient had a BRCA1 & 2 VUS. 
¥The denominator for RAD51C/D mutations and RAD51C/D VUS was not the same as the number of patients sequenced for gBRCA1/2 
mutations (see methods). The denominator for patients in the ‘old criteria’ population from the East of Scotland who received RAD51C/D 
sequencing is not known (NK) because RAD51C/D sequencing was introduced after BRCA1/2 sequencing. 
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Table 4. Germline BRCA1/2 mutation breakdown by cohort and Manchester score. 
 
 
gBRCA 
mutation 
East West Combined 
Manchester 
Score ≥15 
Manchester 
Score <15 
Manchester 
Score ≥15 
Manchester 
Score  <15 
Manchester 
Score ≥15 
Manchester 
Score <15 
Old criteria 
BRCA 1 30/33 (91%) 3/33 (9%) 3/8 (38%) 5/8 (62%) 33/41 (80%) 8/41 (20%) 
BRCA 2 13/15 (87%) 2/15 (13%) 3/7 (43%) 4/7 (57%) 16/22 (73%) 6/22 (27%) 
Prevalent 
population 
BRCA 1 2/6 (33%) 4/6 (67%) 3/4 (75%) 1/4 (25%) 5/10 (50%) 5/10 (50%) 
BRCA 2 3/3 (100%) 0/3 (0%) 3/7 (43%) 4/7 (57%) 6/10 (60%) 4/10 (40%) 
New 
criteria 
BRCA 1 7/12* (58%) 5/12 (42%) 2/3 (67%) 1/3 (33%) 9/15* (60%) 6/15* (40%) 
BRCA 2 3/6* (50%) 3/6 (50%) 5/11 (45%) 6/11 (55%) 8/17* (47%) 9/17* (53%) 
 
*1 ‘new patient’ with Manchester score ≥15 had pathogenic mutations in both BRCA1 and 
BRCA2 
 
 
